Use of pridopidine for treating huntington disease
AssigneePrilenia Neurotherapeutics Ltd.
InventorsMichael HAYDEN, Michal GEVA
Life of this patent
Estimating the term…
Abstract
Provided herein a method of maintaining, improving, or lessening the decline of functional capacity, cognition, motor function, disease progression and quality of life of a subject afflicted with Huntington disease, including those afflicted with early-stage Huntington disease (HD1 and HD2, TFC 7-13) by orally administering to the subject a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
Claims16
A method of treating early stage Huntington disease (HD) [early HD, TFC is 7-13] or symptoms thereof in a human subject wherein the method comprises orally administering to the subject with early HD, TFC 7-13, a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof, wherein the treatment does not include co-administration of antidopaminergic medications (ADMs), with the composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.